Form 4: Takeda Sells HilleVax Stake in XOMA Tender Offer

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. have sold their entire 6,724,000 shares of HilleVax, Inc. common stock for $1.95 per share as part of a tender offer by XOMA Royalty Corporation.

Summary

• Takeda Pharmaceutical Company Limited and its indirect wholly-owned subsidiary, Takeda Vaccines, Inc., reported the sale of 6,724,000 shares of HilleVax, Inc. common stock.
• The transaction occurred on September 17, 2025, with shares sold at a price of $1.95 per share.
• This sale was executed pursuant to a cash tender offer initiated by XOMA Royalty Corporation and its subsidiary, XRA 4 Corp.
• The tender offer, which included an offer price of $1.95 per share plus one non-transferable contractual contingent value right, expired on September 15, 2025.
• Following the reported transaction, Takeda Pharmaceutical Company Limited and Takeda Vaccines, Inc. no longer hold any beneficial ownership in HilleVax, Inc. common stock.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a tender offer, allowing Takeda to fully divest its stake in HilleVax, Inc. at a specified price. This represents a planned and executed exit strategy for Takeda and a defined liquidity event for HilleVax shareholders, indicating a neutral to slightly positive outcome for the parties involved.

Positives

• Takeda successfully divested its entire 6,724,000 share stake in HilleVax, Inc. at a fixed price of $1.95 per share, realizing a clear exit from the investment.
• The transaction was part of a structured tender offer, indicating a clear and organized divestment process for Takeda's holdings.

Future Outlook

The filing does not provide forward-looking statements or guidance from Takeda or HilleVax, as it primarily reports a completed insider transaction related to a tender offer.

Industry Context

This transaction reflects ongoing consolidation and strategic portfolio adjustments within the biotechnology and pharmaceutical sectors. Larger entities like Takeda may divest non-core assets or investments, while other companies like XOMA seek to acquire promising assets or companies through tender offers, which is a common mechanism for M&A activity in these industries.

Stakeholder Impact

• Shareholders (HilleVax): Shareholders who tendered their shares received $1.95 per share in cash and one non-transferable contractual contingent value right, providing liquidity and a defined return.
• Takeda Pharmaceutical Co Ltd: Successfully exited its investment in HilleVax, Inc., divesting 6,724,000 shares and receiving proceeds from the sale.
• XOMA Royalty Corporation: Successfully acquired a significant block of HilleVax shares, moving closer to or completing its acquisition of the company.

Key Dates

Keywords

HilleVax, HLVX, Takeda, XOMA, tender offer, common stock, beneficial ownership, divestment, insider transaction